High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2022 Jun 20

PMID 35723969

Authors

Farshad Guirakhoo

Shixia Wang

Chang Yi Wang

Hui Kai Kuo

Wen Jiun Peng

Hope Liu

Lixia Wang

Marina Johnson

Adam Hunt

Mei Mei Hu

Thomas P Monath

Alexander Rumyantsev

David Goldblatt

Affiliations

Soon will be listed here.

Abstract

The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.

Citing Articles

COVID-19 Vaccines: Where Did We Stand at the End of 2023?.

Lundstrom K Viruses. 2024; 16(2).

PMID: 38399979 PMC: 10893040. DOI: 10.3390/v16020203.

RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques.

Wang S, Guirakhoo F, Periasamy S, Ryan V, Wiggins J, Subramani C Vaccines (Basel). 2024; 12(1).

PMID: 38250853 PMC: 10818657. DOI: 10.3390/vaccines12010040.

Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines.

Deng Y, Atyeo C, Yuan D, Chicz T, Tibbitts T, Gorman M Cell Rep. 2023; 42(11):113292.

PMID: 38007686 PMC: 11289877. DOI: 10.1016/j.celrep.2023.113292.

Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.

Perdiguero B, Marcos-Villar L, Lopez-Bravo M, Sanchez-Cordon P, Zamora C, Valverde J Front Immunol. 2023; 14:1160065.

PMID: 37404819 PMC: 10316789. DOI: 10.3389/fimmu.2023.1160065.

Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.

Guan X, Yang Y, Du L Expert Rev Vaccines. 2023; 22(1):422-439.

PMID: 37161869 PMC: 10355161. DOI: 10.1080/14760584.2023.2211153.

References

Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D . Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2021; 40(2):306-315. PMC: 8673730. DOI: 10.1016/j.vaccine.2021.12.006. View

Viana R, Moyo S, Amoako D, Tegally H, Scheepers C, Althaus C . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022; 603(7902):679-686. PMC: 8942855. DOI: 10.1038/s41586-022-04411-y. View

Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E . Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386(16):1532-1546. PMC: 8908811. DOI: 10.1056/NEJMoa2119451. View

Perez-Then E, Lucas C, Silva Monteiro V, Miric M, Brache V, Cochon L . Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat Med. 2022; 28(3):481-485. PMC: 8938264. DOI: 10.1038/s41591-022-01705-6. View

Pajon R, Doria-Rose N, Shen X, Schmidt S, ODell S, McDanal C . SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022; 386(11):1088-1091. PMC: 8809504. DOI: 10.1056/NEJMc2119912. View

Maciola A, La Raja M, Pacenti M, Salata C, De Silvestro G, Rosato A . Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Front Immunol. 2022; 13:830710. PMC: 8841804. DOI: 10.3389/fimmu.2022.830710. View

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

Chandrashekar A, Yu J, McMahan K, Jacob-Dolan C, Liu J, He X . Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. Cell. 2022; 185(9):1549-1555.e11. PMC: 8926910. DOI: 10.1016/j.cell.2022.03.024. View

Wang C, Hwang K, Kuo H, Peng W, Shen Y, Kuo B . A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. J Clin Invest. 2022; 132(10). PMC: 9106357. DOI: 10.1172/JCI157707. View

10.

Kleanthous H, Silverman J, Makar K, Yoon I, Jackson N, Vaughn D . Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. NPJ Vaccines. 2021; 6(1):128. PMC: 8553742. DOI: 10.1038/s41541-021-00393-6. View

11.

Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J . Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022; 607(7917):128-134. PMC: 9259484. DOI: 10.1038/s41586-022-04778-y. View

12.

Cromer D, Steain M, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2021; 3(1):e52-e61. PMC: 8592563. DOI: 10.1016/S2666-5247(21)00267-6. View

13.

Muik A, Lui B, Wallisch A, Bacher M, Muhl J, Reinholz J . Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022; 375(6581):678-680. PMC: 9836206. DOI: 10.1126/science.abn7591. View